Biogen Quarterly Income Statements Chart
Quarterly
|
Annual
Biogen Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-12-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product revenue | 1,878,700,000 | 1,726,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue from anti-cd20 therapeutic programs | 467,300,000 | 378,200,000 | 465,200,000 | 446,200,000 | 444,500,000 | 394,000,000 | 435,800,000 | 420,900,000 | 433,400,000 | 399,500,000 | 447,900,000 | 416,900,000 | 436,300,000 | 399,400,000 | 414,100,000 | 415,400,000 | 440,000,000 | 389,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| alzheimer's collaboration revenue | 54,900,000 | 33,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contract manufacturing, royalty and other revenue | 244,600,000 | 293,300,000 | 97,000,000 | 250,200,000 | 120,800,000 | 184,600,000 | 118,100,000 | 304,200,000 | 197,500,000 | 319,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total revenue | 2,645,500,000 | 2,431,000,000 | 2,454,700,000 | 2,465,800,000 | 2,464,900,000 | 2,290,500,000 | 2,386,300,000 | 2,530,300,000 | 2,456,000,000 | 2,463,000,000 | 2,544,000,000 | 2,508,500,000 | 2,589,100,000 | 2,531,800,000 | 2,733,800,000 | 2,778,900,000 | 2,775,000,000 | 2,694,000,000 | 2,852,600,000 | 3,376,100,000 | 3,681,600,000 | 3,534,300,000 | 3,671,300,000 | 3,600,100,000 | 3,616,700,000 | 3,489,800,000 | 3,526,300,000 | 3,439,000,000 | 3,356,500,000 | 3,131,100,000 | 3,307,000,000 | 3,077,800,000 | 3,078,400,000 | 2,810,700,000 | 2,872,000,000 | 2,955,800,000 | 2,894,200,000 | 2,726,800,000 | 2,839,336,000 | 2,777,859,000 | 2,591,642,000 | 2,554,963,000 | 2,640,675,000 | 2,511,446,000 | 2,421,452,000 | 2,129,751,000 | 1,965,850,000 | 1,827,780,000 | 1,723,473,000 | 1,415,096,000 | 1,417,941,000 | 1,385,554,000 | 1,420,951,000 | 1,292,014,000 | 3,738,700,000 | 1,309,934,000 | 1,208,647,000 | 1,203,342,000 | 1,175,800,000 | 1,212,702,000 | 1,108,860,000 | 3,256,830,000 | 1,120,518,000 | 1,093,289,000 | 1,036,484,000 | 1,068,913,000 | 1,092,964,000 | 993,444,000 | 942,186,000 | 893,300,000 | 789,231,000 | 773,176,000 | 715,910,000 | 708,341,000 | 703,492,000 | 660,041,000 | 611,175,000 | 632,853,000 | 596,211,000 | 605,634,000 | 587,802,000 | ||
| yoy | 7.33% | 6.13% | 2.87% | -2.55% | 0.36% | -7.00% | -6.20% | 0.87% | -5.14% | -2.72% | -6.94% | -9.73% | -6.70% | -6.02% | -4.16% | -17.69% | -24.63% | -23.78% | -22.30% | -6.22% | 1.79% | 1.28% | 4.11% | 4.68% | 7.75% | 11.46% | 6.63% | 11.74% | 9.03% | 11.40% | 15.15% | 4.13% | 6.36% | 3.08% | 1.15% | 6.41% | 11.67% | 6.73% | 7.52% | 10.61% | 7.03% | 19.97% | 34.33% | 37.40% | 40.50% | 50.50% | 38.64% | 31.92% | 21.29% | 9.53% | -62.07% | 5.77% | 17.57% | 7.37% | 11.41% | -0.33% | 8.52% | 4.93% | 10.92% | 6.98% | 204.69% | 2.52% | 10.05% | 10.01% | 19.66% | 38.48% | 28.49% | 31.61% | 26.11% | 12.19% | 17.14% | 17.14% | 11.93% | 17.99% | 8.98% | 3.98% | |||||||
| qoq | 8.82% | -0.97% | -0.45% | 0.04% | 7.61% | -4.01% | -5.69% | 3.03% | -0.28% | -3.18% | 1.42% | -3.11% | 2.26% | -7.39% | -1.62% | 0.14% | 3.01% | -5.56% | -15.51% | -8.30% | 4.17% | -3.73% | 1.98% | -0.46% | 3.64% | -1.04% | 2.54% | 2.46% | 7.20% | -5.32% | 7.45% | -0.02% | 9.52% | -2.13% | -2.84% | 2.13% | 6.14% | -3.96% | 2.21% | 7.19% | 1.44% | -3.25% | 5.15% | 3.72% | 13.70% | 8.34% | 7.55% | 6.05% | 21.79% | -0.20% | 2.34% | -2.49% | 9.98% | -65.44% | 185.41% | 8.38% | 0.44% | -3.04% | 9.36% | -65.95% | 190.65% | 2.49% | 5.48% | -3.03% | -2.20% | 10.02% | 5.44% | 5.47% | 13.19% | 2.08% | 8.00% | 1.07% | 0.69% | 6.58% | 8.00% | -3.43% | 6.15% | -1.56% | 3.03% | ||||
| cost and expense: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales, excluding amortization and impairment of acquired intangible assets | 605,000,000 | 629,300,000 | 583,500,000 | 638,700,000 | 546,000,000 | 542,200,000 | 618,300,000 | 659,600,000 | 592,700,000 | 662,800,000 | 570,900,000 | 469,500,000 | 484,000,000 | 753,900,000 | 660,100,000 | 511,800,000 | 459,700,000 | 478,100,000 | 490,600,000 | 449,100,000 | 411,100,000 | 454,300,000 | 447,100,000 | 430,000,000 | 476,300,000 | 602,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 399,000,000 | 434,100,000 | 532,300,000 | 542,700,000 | 513,900,000 | 452,900,000 | 570,900,000 | 736,300,000 | 584,200,000 | 570,600,000 | 601,600,000 | 549,200,000 | 528,600,000 | 551,700,000 | 699,500,000 | 702,400,000 | 585,100,000 | 514,200,000 | 1,726,100,000 | 1,140,900,000 | 647,600,000 | 476,300,000 | 691,700,000 | 540,400,000 | 484,800,000 | 563,700,000 | 611,600,000 | 507,900,000 | 981,000,000 | 496,700,000 | 587,600,000 | 446,400,000 | 796,200,000 | 423,400,000 | 533,900,000 | 529,000,000 | 473,100,000 | 437,300,000 | 541,660,000 | 519,863,000 | 490,728,000 | 460,549,000 | 500,091,000 | 417,174,000 | 447,273,000 | 528,884,000 | 422,233,000 | 410,017,000 | 327,463,000 | 284,340,000 | 345,181,000 | 304,217,000 | 329,559,000 | 355,962,000 | 918,211,000 | 301,391,000 | 285,644,000 | 293,633,000 | 331,675,000 | 307,030,000 | 979,013,000 | 304,055,000 | 416,453,000 | 279,478,000 | 292,767,000 | 268,800,000 | 252,259,000 | 258,232,000 | 229,292,000 | 286,274,000 | 218,149,000 | 191,449,000 | 199,480,000 | 211,033,000 | 161,985,000 | 145,892,000 | 168,314,000 | 227,039,000 | 179,843,000 | 178,784,000 | |||
| acquired in-process research and development, upfront and milestone expense | 46,600,000 | 200,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 583,800,000 | 572,500,000 | 680,000,000 | 588,400,000 | 553,800,000 | 581,500,000 | 608,500,000 | 788,200,000 | 548,000,000 | 605,000,000 | 632,800,000 | 563,300,000 | 572,600,000 | 634,900,000 | 787,900,000 | 654,100,000 | 637,300,000 | 595,000,000 | 806,200,000 | 573,100,000 | 555,100,000 | 570,100,000 | 664,900,000 | 554,500,000 | 587,600,000 | 567,700,000 | 591,100,000 | 497,700,000 | 516,200,000 | 501,300,000 | 572,400,000 | 433,800,000 | 430,200,000 | 499,100,000 | 495,500,000 | 462,700,000 | 492,400,000 | 497,300,000 | 583,017,000 | 477,827,000 | 491,895,000 | 560,361,000 | 573,610,000 | 570,436,000 | 576,622,000 | 511,674,000 | 522,857,000 | 405,584,000 | 431,012,000 | 352,598,000 | 375,977,000 | 299,631,000 | 301,767,000 | 300,089,000 | 794,735,000 | 261,398,000 | 266,301,000 | 244,516,000 | 262,322,000 | 248,664,000 | 684,279,000 | 226,755,000 | 220,829,000 | 221,830,000 | 230,963,000 | 232,824,000 | 245,689,000 | 215,829,000 | 193,730,000 | 190,644,000 | 203,668,000 | 188,061,000 | 192,234,000 | 168,153,000 | 170,289,000 | 154,391,000 | 169,121,000 | 161,410,000 | 155,754,000 | 158,458,000 | |||
| amortization and impairment of acquired intangible assets | 130,900,000 | 111,800,000 | 151,200,000 | 130,300,000 | 86,900,000 | 78,300,000 | 76,600,000 | 60,900,000 | 52,900,000 | 50,200,000 | 175,000,000 | 56,500,000 | 67,500,000 | 66,900,000 | 68,100,000 | 111,000,000 | 604,100,000 | 98,100,000 | 249,200,000 | 82,600,000 | 61,500,000 | 71,500,000 | 67,700,000 | 283,900,000 | 70,100,000 | 68,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| collaboration profit sharing/ | 75,000,000 | 58,100,000 | 57,100,000 | 69,300,000 | 62,400,000 | 65,600,000 | 54,300,000 | 50,500,000 | 56,900,000 | 57,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (gain) loss on fair value remeasurement of contingent consideration | 13,200,000 | 9,600,000 | 3,900,000 | 23,800,000 | -195,400,000 | -2,100,000 | -4,500,000 | -7,100,000 | -1,600,000 | -15,600,000 | 300,000 | -33,800,000 | -62,800,000 | -29,000,000 | 10,000,000 | -4,600,000 | 2,600,000 | -57,800,000 | -20,000,000 | 79,300,000 | -87,900,000 | -5,600,000 | 15,300,000 | 30,000,000 | 21,200,000 | 10,000,000 | 4,700,000 | 5,900,000 | 10,600,000 | 2,300,000 | 24,613,000 | 244,000 | -2,201,000 | 7,844,000 | 7,320,000 | -49,433,000 | 4,019,000 | -799,000 | 2,436,000 | -97,000 | -5,163,000 | ||||||||||||||||||||||||||||||||||||||||||
| restructuring charges | -700,000 | 35,300,000 | 5,300,000 | 6,800,000 | 6,600,000 | 11,500,000 | 98,800,000 | 76,000,000 | 34,400,000 | 9,600,000 | 7,000,000 | 15,400,000 | 70,600,000 | 38,100,000 | 300,000 | 800,000 | 400,000 | 2,800,000 | 6,000,000 | 1,600,000 | 1,600,000 | 11,800,000 | 11,600,000 | 9,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of priority review voucher | -88,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | 48,700,000 | 68,400,000 | 149,900,000 | 14,800,000 | 85,200,000 | 93,700,000 | 67,300,000 | 300,000,000 | -121,200,000 | 69,400,000 | 113,100,000 | -56,000,000 | -428,600,000 | -263,300,000 | -182,100,000 | -502,900,000 | 96,400,000 | -506,900,000 | 683,500,000 | -128,600,000 | 63,000,000 | -120,500,000 | -49,300,000 | -27,300,000 | -197,400,000 | 357,300,000 | -28,600,000 | 115,100,000 | -34,500,000 | -41,000,000 | -66,000,000 | -43,600,000 | -68,200,000 | -37,600,000 | -48,000,000 | -58,100,000 | -58,500,000 | -52,800,000 | -82,412,000 | -15,413,000 | -10,889,000 | -14,986,000 | -8,751,000 | -16,290,000 | 4,861,000 | -5,601,000 | -5,405,000 | -4,640,000 | -10,428,000 | -14,457,000 | -14,290,000 | -4,548,000 | 2,950,000 | 15,144,000 | -5,750,000 | -7,727,000 | -11,728,000 | 9,951,000 | 1,012,000 | -8,386,000 | 27,892,000 | 9,360,000 | 14,680,000 | 6,846,000 | -34,850,000 | -24,725,000 | -5,463,000 | 370,000 | 32,631,000 | 44,904,000 | 31,586,000 | 21,702,000 | -10,647,000 | 22,319,000 | 21,806,000 | 18,665,000 | 11,837,000 | 11,192,000 | 6,051,000 | -8,926,000 | |||
| total cost and expense | 1,901,500,000 | 2,119,800,000 | 2,163,200,000 | 2,014,800,000 | 1,766,200,000 | 1,825,700,000 | 2,094,700,000 | 2,671,500,000 | 1,747,900,000 | 2,024,700,000 | 1,940,200,000 | 1,137,400,000 | 1,319,600,000 | 1,921,100,000 | 2,146,700,000 | 1,984,900,000 | 2,289,300,000 | 1,720,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax (benefit) expense | 744,000,000 | 311,200,000 | 403,625,000 | 451,000,000 | 698,700,000 | 464,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | 109,200,000 | 70,700,000 | 24,800,000 | 62,500,000 | 115,100,000 | 71,400,000 | 42,700,000 | -72,900,000 | 114,800,000 | 50,700,000 | 54,300,000 | 236,200,000 | 216,700,000 | 125,600,000 | 443,200,000 | -25,900,000 | -409,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to biogen inc. | 634,800,000 | 240,500,000 | 266,700,000 | 388,500,000 | 583,600,000 | 393,400,000 | 249,700,000 | -68,100,000 | 591,600,000 | 387,900,000 | 550,400,000 | 1,134,700,000 | 1,058,000,000 | 303,800,000 | 368,200,000 | 329,200,000 | 448,500,000 | 410,200,000 | 357,900,000 | 701,500,000 | 1,542,100,000 | 1,399,100,000 | 1,439,700,000 | 1,545,900,000 | 1,494,100,000 | 1,408,800,000 | 946,800,000 | 1,444,400,000 | 866,600,000 | 1,172,900,000 | -297,400,000 | 1,226,100,000 | 862,800,000 | 747,600,000 | 649,200,000 | 1,032,900,000 | 1,049,800,000 | 970,900,000 | 831,561,000 | 965,622,000 | 927,276,000 | 822,541,000 | |||||||||||||||||||||||||||||||||||||||||
| net income per share | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic earnings per share attributable to biogen inc. | 4.33 | 1.65 | 1.83 | 2.67 | 4.01 | 2.71 | 1.72 | -0.47 | 4.09 | 2.69 | 3.84 | 7.86 | 7.25 | 2.06 | 2.51 | 2.22 | 3 | 2.7 | 2.57 | 4.47 | 9.6 | 8.1 | 8.09 | 8.4 | 7.85 | 7.17 | 4.77 | 7.17 | 4.18 | 5.55 | -1.38 | 5.8 | 4.07 | 3.47 | 3.01 | 4.72 | 4.79 | 4.44 | 3.78 | 4.16 | 3.94 | 3.5 | |||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share attributable to biogen inc. | 4.33 | 1.64 | 1.83 | 2.66 | 4 | 2.7 | 1.71 | -0.47 | 4.07 | 2.67 | 3.8 | 7.84 | 7.24 | 2.06 | 2.5 | 2.22 | 2.99 | 2.69 | 2.55 | 4.46 | 9.59 | 8.08 | 8.07 | 8.39 | 7.85 | 7.15 | 4.75 | 7.15 | 4.18 | 5.54 | -1.38 | 5.79 | 4.07 | 3.46 | 3.01 | 4.71 | 4.79 | 4.43 | 3.77 | 4.15 | 3.93 | 3.49 | |||||||||||||||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | 254.9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product | 1,345,225,000 | 1,769,400,000 | 1,899,600,000 | 1,711,900,000 | 1,353,575,000 | 1,805,200,000 | 1,845,800,000 | 1,763,300,000 | 1,904,500,000 | 1,962,100,000 | 2,054,900,000 | 2,066,300,000 | 2,193,500,000 | 2,205,700,000 | 2,236,000,000 | 2,211,700,000 | 2,301,600,000 | 2,690,300,000 | 2,795,700,000 | 2,904,600,000 | 2,924,800,000 | 2,894,700,000 | 2,880,300,000 | 2,680,000,000 | 2,825,700,000 | 2,780,100,000 | 2,757,500,000 | 2,523,500,000 | 2,712,400,000 | 2,622,500,000 | 2,639,700,000 | 2,380,100,000 | 2,502,900,000 | 2,539,600,000 | 2,466,000,000 | 2,309,400,000 | 2,425,895,000 | 2,391,717,000 | 2,198,566,000 | 2,172,322,000 | 2,286,981,000 | 2,117,366,000 | 2,056,292,000 | 1,742,765,000 | 1,607,080,000 | 1,453,554,000 | 1,385,918,000 | 1,095,779,000 | 1,074,676,000 | 1,039,110,000 | 1,076,800,000 | 975,488,000 | 2,860,360,000 | 975,757,000 | 956,703,000 | 907,102,000 | 859,235,000 | 824,220,000 | 2,351,252,000 | 801,689,000 | 790,970,000 | 733,409,000 | 731,835,000 | 758,260,000 | 684,486,000 | 665,070,000 | 604,227,000 | 529,581,000 | 518,625,000 | 484,388,000 | 463,617,000 | 475,096,000 | 436,081,000 | 406,519,000 | 429,231,000 | 391,366,000 | 398,822,000 | 397,584,000 | |||||
| net income | 266,700,000 | 388,500,000 | 583,600,000 | 393,400,000 | 248,900,000 | -68,300,000 | 593,300,000 | 387,600,000 | 549,500,000 | 1,134,900,000 | 1,058,700,000 | 218,500,000 | -20,500,000 | 318,100,000 | 1,025,500,000 | 404,600,000 | 357,600,000 | 703,900,000 | 1,606,500,000 | 1,392,600,000 | 1,439,700,000 | 1,545,900,000 | 1,494,100,000 | 1,408,800,000 | 944,900,000 | 1,442,900,000 | 915,000,000 | 1,171,200,000 | -166,300,000 | 1,226,100,000 | 862,800,000 | 747,500,000 | 647,900,000 | 1,030,200,000 | 1,048,400,000 | 969,200,000 | 828,708,000 | 1,019,493,000 | 924,825,000 | 820,174,000 | 882,585,000 | 856,120,000 | 723,132,000 | 479,728,000 | 457,306,000 | 487,616,000 | 490,670,000 | 426,749,000 | 292,127,000 | 398,400,000 | 387,141,000 | 302,366,000 | 913,024,000 | 353,662,000 | 304,049,000 | 308,766,000 | 294,649,000 | 219,993,000 | 697,460,000 | 279,602,000 | 144,885,000 | 246,579,000 | 206,654,000 | 206,788,000 | 206,628,000 | 163,097,000 | 201,150,000 | 119,381,000 | 186,140,000 | 131,501,000 | 108,556,000 | 156,599,000 | -170,613,000 | 122,969,000 | 55,562,000 | 27,185,000 | 34,504,000 | 43,458,000 | |||||
| yoy | 7.15% | -668.81% | -1.63% | 1.50% | -54.70% | -106.02% | -43.96% | 77.39% | -2780.49% | 256.77% | 3.24% | -46.00% | -105.73% | -54.81% | -36.17% | -70.95% | -75.16% | -54.47% | 7.52% | -1.15% | 52.37% | 7.14% | 63.29% | 20.29% | -668.19% | 17.68% | 6.05% | 56.68% | -125.67% | 19.02% | -17.70% | -22.87% | -21.82% | 1.05% | 13.36% | 18.17% | -6.10% | 19.08% | 27.89% | 70.97% | 93.00% | 75.57% | 47.38% | 12.41% | 56.54% | 22.39% | 26.74% | 41.14% | -68.00% | 12.65% | 27.33% | -2.07% | 3.19% | 40.35% | 103.37% | -10.78% | 237.50% | 35.21% | -29.88% | 51.19% | 2.74% | 73.22% | 11.01% | 24.03% | 85.30% | -23.77% | -209.10% | 6.94% | 95.38% | 476.05% | -594.47% | 182.96% | |||||||||||
| qoq | -31.35% | -33.43% | 48.35% | 58.06% | -464.42% | -111.51% | 53.07% | -29.46% | -51.58% | 7.20% | 384.53% | -1165.85% | -106.44% | -68.98% | 153.46% | 13.14% | -49.20% | -56.18% | 15.36% | -3.27% | -6.87% | 3.47% | 6.05% | 49.10% | -34.51% | 57.69% | -21.88% | -804.27% | -113.56% | 42.11% | 15.42% | 15.37% | -37.11% | -1.74% | 8.17% | 16.95% | -18.71% | 10.24% | 12.76% | -7.07% | 3.09% | 18.39% | 50.74% | 4.90% | -6.22% | -0.62% | 14.98% | 46.08% | -26.67% | 2.91% | 28.04% | -66.88% | 158.16% | 16.32% | -1.53% | 33.94% | -68.46% | 149.45% | 92.98% | -41.24% | 19.32% | -0.06% | 0.08% | 26.69% | -18.92% | 68.49% | -35.86% | 41.55% | 21.14% | -30.68% | -191.79% | -238.74% | 121.32% | 104.38% | -21.21% | -20.60% | |||||||
| net income margin % | 0% | 0% | 10.86% | 15.76% | 23.68% | 17.18% | 10.43% | -2.70% | 24.16% | 15.74% | 21.60% | 45.24% | 40.89% | 8.63% | -0.75% | 11.45% | 36.95% | 15.02% | 12.54% | 20.85% | 43.64% | 39.40% | 39.21% | 42.94% | 41.31% | 40.37% | 26.80% | 41.96% | 27.26% | 37.41% | -5.03% | 39.84% | 28.03% | 26.59% | 22.56% | 34.85% | 36.22% | 35.54% | 29.19% | 36.70% | 35.68% | 32.10% | 33.42% | 34.09% | 29.86% | 22.53% | 23.26% | 26.68% | 28.47% | 30.16% | 20.60% | 28.75% | 27.25% | 23.40% | 24.42% | 27.00% | 25.16% | 25.66% | 0% | 24.30% | 19.84% | 21.42% | 24.95% | 13.25% | 23.79% | 19.33% | 18.92% | 20.80% | 17.31% | 22.52% | 15.13% | 24.07% | 18.37% | 15.33% | 22.26% | -25.85% | 20.12% | 8.78% | 4.56% | 5.70% | 7.39% | ||
| net income attributable to noncontrolling interests, net of tax | -800,000 | -200,000 | 1,700,000 | -300,000 | -900,000 | 200,000 | 700,000 | -85,300,000 | -388,700,000 | -11,100,000 | 577,000,000 | -5,600,000 | -300,000 | 2,400,000 | 64,400,000 | -6,500,000 | -1,900,000 | -1,500,000 | 48,400,000 | -1,700,000 | 131,100,000 | -100,000 | -1,300,000 | -2,700,000 | -1,400,000 | -1,700,000 | -2,853,000 | 53,871,000 | -2,451,000 | -2,367,000 | -879,000 | -738,000 | 8,626,000 | -228,000 | 295,000 | -295,000 | 30,422,000 | 1,836,000 | 16,015,000 | 14,435,000 | |||||||||||||||||||||||||||||||||||||||||||
| gain on sale of building | -503,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax (benefit) expense and equity in loss of investee, net of tax | 291,600,000 | -141,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| equity in (income) loss of investee, net of tax | -5,900,000 | 3,300,000 | -17,700,000 | -1,100,000 | -34,300,000 | 18,200,000 | -18,000,000 | 13,100,000 | -15,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue from leqembi collaboration | -20,700,000 | -18,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax expense and equity in loss of investee, net of tax | 708,100,000 | 438,300,000 | 603,800,000 | 1,371,100,000 | 1,269,500,000 | 347,400,000 | 405,000,000 | 291,100,000 | 582,100,000 | 467,000,000 | 352,900,000 | 957,800,000 | 2,037,500,000 | 1,699,400,000 | 1,728,400,000 | 1,779,000,000 | 1,758,500,000 | 1,860,000,000 | 1,414,500,000 | 1,812,700,000 | 1,178,700,000 | 1,493,700,000 | 1,399,800,000 | 1,609,900,000 | 1,132,400,000 | 986,700,000 | 838,200,000 | 1,367,200,000 | 1,402,000,000 | 1,325,600,000 | 1,085,785,000 | 1,356,419,000 | 1,222,207,000 | 1,102,889,000 | 1,151,012,000 | 1,136,288,000 | 993,586,000 | 665,747,000 | 652,521,000 | 679,891,000 | 652,099,000 | 496,068,000 | 431,217,000 | 530,702,000 | 508,673,000 | ||||||||||||||||||||||||||||||||||||||
| other | 191,600,000 | 129,500,000 | 97,900,000 | 66,100,000 | 126,200,000 | 157,800,000 | 99,000,000 | 93,300,000 | 132,000,000 | 125,700,000 | 407,600,000 | 109,300,000 | 145,700,000 | 109,600,000 | 160,000,000 | 292,400,000 | 165,700,000 | 147,200,000 | 108,600,000 | 164,400,000 | 179,600,000 | 48,800,000 | 41,600,000 | 90,000,000 | 50,900,000 | 98,600,000 | 79,000,000 | 87,900,000 | 79,543,000 | 48,961,000 | 55,566,000 | 52,030,000 | 49,164,000 | 103,402,000 | 61,864,000 | 90,101,000 | 89,354,000 | 71,016,000 | 48,770,000 | 54,711,000 | 62,317,000 | 58,652,000 | 59,521,000 | 31,974,000 | 148,214,000 | 67,706,000 | 35,486,000 | 40,116,000 | 47,096,000 | 29,712,000 | 29,893,000 | 18,333,000 | 25,013,000 | 23,961,000 | 24,358,000 | ||||||||||||||||||||||||||||
| collaboration profit sharing | 35,200,000 | 45,300,000 | 29,400,000 | -117,300,000 | -67,300,000 | 21,200,000 | -15,200,000 | 68,500,000 | 66,400,000 | 73,000,000 | 21,800,000 | 71,800,000 | 59,800,000 | 60,200,000 | 63,500,000 | 58,100,000 | 55,800,000 | 47,500,000 | 39,200,000 | 42,500,000 | 29,800,000 | 35,200,000 | 26,500,000 | 20,800,000 | 11,100,000 | 4,700,000 | -5,600,000 | 85,357,000 | 77,944,000 | 75,545,000 | 78,511,000 | 85,894,000 | 236,296,000 | 81,475,000 | 88,050,000 | 74,794,000 | 62,692,000 | 63,557,000 | 155,207,000 | 60,697,000 | 49,138,000 | 42,773,000 | 37,673,000 | 43,533,000 | 33,429,000 | 21,406,000 | 13,909,000 | 5,842,000 | -105,000 | -5,567,000 | |||||||||||||||||||||||||||||||||
| acquired in-process research and development | 18,000,000 | 75,000,000 | 27,500,000 | 75,000,000 | 10,000,000 | 120,000,000 | 39,976,000 | 35,808,000 | 29,959,000 | 18,405,000 | 330,520,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from operations | 610,700,000 | 587,100,000 | 794,000,000 | 485,700,000 | 973,900,000 | -330,600,000 | 1,086,400,000 | 1,974,500,000 | 1,819,900,000 | 1,777,700,000 | 1,806,300,000 | 1,955,900,000 | 1,502,700,000 | 1,443,100,000 | 1,697,600,000 | 1,213,200,000 | 1,534,700,000 | 1,465,800,000 | 1,653,500,000 | 1,200,600,000 | 1,024,300,000 | 886,200,000 | 1,425,300,000 | 1,460,500,000 | 1,378,400,000 | 1,168,197,000 | 1,371,832,000 | 1,233,096,000 | 1,117,875,000 | 1,159,763,000 | 1,152,578,000 | 988,725,000 | 671,348,000 | 657,926,000 | 684,531,000 | 662,527,000 | 510,525,000 | 445,507,000 | 535,250,000 | 505,723,000 | 369,370,000 | 1,236,198,000 | 488,493,000 | 410,813,000 | 416,283,000 | 194,100,000 | 395,880,000 | 303,689,000 | 911,249,000 | 384,178,000 | 222,914,000 | 304,958,000 | 324,960,000 | 345,850,000 | 296,797,000 | 246,004,000 | 262,430,000 | 129,210,000 | 206,440,000 | 181,692,000 | 191,718,000 | 197,328,000 | -122,015,000 | 172,989,000 | 93,299,000 | 21,165,000 | 46,301,000 | 75,274,000 | |||||||||||||||
| yoy | -37.29% | -277.59% | -26.91% | -75.40% | -46.49% | -118.60% | -39.85% | 0.95% | 21.11% | 23.19% | 6.40% | 61.22% | -2.09% | -1.55% | 2.67% | 1.05% | 49.83% | 65.40% | 16.01% | -17.80% | -25.69% | -24.14% | 3.90% | 18.44% | 23.31% | 0.73% | 19.02% | 24.72% | 66.51% | 76.28% | 68.37% | 49.24% | 31.50% | 47.68% | 27.89% | 31.01% | 38.22% | -63.96% | 9.57% | 23.10% | -11.27% | 151.67% | 3.77% | 37.08% | -49.48% | 77.59% | -0.42% | 180.42% | 11.08% | -24.89% | 23.96% | 23.83% | 167.67% | 43.77% | 35.40% | 36.88% | -34.52% | -269.19% | 5.03% | 105.49% | 832.33% | -363.53% | 129.81% | ||||||||||||||||||||
| qoq | 4.02% | -26.06% | 63.48% | -50.13% | -394.59% | -130.43% | -44.98% | 8.49% | 2.37% | -1.58% | -7.65% | 30.16% | 4.13% | -14.99% | 39.93% | -20.95% | 4.70% | -11.35% | 37.72% | 17.21% | 15.58% | -37.82% | -2.41% | 5.96% | 17.99% | -14.84% | 11.25% | 10.31% | -3.61% | 0.62% | 16.57% | 47.27% | 2.04% | -3.89% | 3.32% | 29.77% | 14.59% | -16.77% | 5.84% | 36.92% | -70.12% | 153.06% | 18.91% | -1.31% | -50.97% | 30.36% | -66.67% | 137.19% | 72.34% | -26.90% | -6.16% | -6.04% | 16.53% | 20.65% | -6.26% | 103.10% | -37.41% | 13.62% | -5.23% | -2.84% | -261.72% | -170.53% | 85.41% | 340.82% | -54.29% | -38.49% | |||||||||||||||||
| operating margin % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 24.12% | 21.48% | 28.57% | 17.50% | 36.15% | -11.59% | 32.18% | 53.63% | 51.49% | 48.42% | 50.17% | 54.08% | 43.06% | 40.92% | 49.36% | 36.14% | 49.01% | 44.32% | 53.72% | 39.00% | 36.44% | 30.86% | 48.22% | 50.46% | 50.55% | 41.14% | 49.38% | 47.58% | 43.75% | 43.92% | 45.89% | 40.83% | 31.52% | 33.47% | 37.45% | 38.44% | 36.08% | 31.42% | 38.63% | 35.59% | 28.59% | 33.06% | 37.29% | 33.99% | 34.59% | 16.51% | 32.64% | 27.39% | 27.98% | 34.29% | 20.39% | 29.42% | 30.40% | 31.64% | 29.88% | 26.11% | 29.38% | 16.37% | 26.70% | 25.38% | 27.07% | 28.05% | -18.49% | 28.30% | 14.74% | 3.55% | 7.65% | 12.81% | ||
| income tax expense | 44,200,000 | 13,300,000 | 240,800,000 | 446,100,000 | 292,000,000 | 276,100,000 | 211,300,000 | 248,100,000 | 422,500,000 | 469,600,000 | 369,800,000 | 263,700,000 | 322,500,000 | 1,566,100,000 | 383,800,000 | 269,600,000 | 239,200,000 | 190,300,000 | 337,000,000 | 353,600,000 | 356,400,000 | 257,125,000 | 330,093,000 | 292,501,000 | 281,881,000 | 268,233,000 | 274,774,000 | 268,521,000 | 178,414,000 | 190,261,000 | 186,105,000 | 159,140,000 | 65,508,000 | 136,341,000 | 131,044,000 | 121,021,000 | 82,148,000 | 317,424,000 | 127,104,000 | 95,036,000 | 117,468,000 | 102,243,000 | 75,310,000 | 241,681,000 | 113,936,000 | 92,709,000 | 65,225,000 | 83,456,000 | 114,337,000 | 84,706,000 | 83,277,000 | 93,911,000 | 54,733,000 | 51,886,000 | 71,893,000 | 72,515,000 | 63,048,000 | 70,404,000 | |||||||||||||||||||||||||
| revenues: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenues from anti-cd20 therapeutic programs | 419,000,000 | 560,100,000 | 478,300,000 | 520,400,000 | 600,800,000 | 595,800,000 | 576,400,000 | 517,400,000 | 534,900,000 | 511,700,000 | 490,400,000 | 443,200,000 | 415,000,000 | 406,500,000 | 397,100,000 | 340,600,000 | 318,200,000 | 317,600,000 | 349,200,000 | 329,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost and expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on divestiture of hillerød, denmark manufacturing operations | -40,200,000 | -17,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total cost and expenses | 3,183,200,000 | 2,289,700,000 | 1,707,100,000 | 1,714,400,000 | 1,893,600,000 | 1,793,800,000 | 1,660,800,000 | 1,987,100,000 | 2,083,200,000 | 1,741,400,000 | 2,143,300,000 | 1,596,400,000 | 1,841,200,000 | 1,424,300,000 | 1,877,800,000 | 1,786,400,000 | 1,985,800,000 | 1,530,500,000 | 1,433,700,000 | 1,348,400,000 | 1,671,139,000 | 1,406,027,000 | 1,358,546,000 | 1,437,088,000 | 1,485,532,000 | 1,363,247,000 | 1,436,627,000 | 1,462,262,000 | 1,315,503,000 | 1,150,198,000 | 1,066,265,000 | 909,622,000 | 987,507,000 | 882,023,000 | 915,228,000 | 922,644,000 | 2,502,502,000 | 821,441,000 | 797,834,000 | 787,059,000 | |||||||||||||||||||||||||||||||||||||||||||
| equity in loss of investee, net of tax | 14,800,000 | 12,600,000 | 21,800,000 | 16,300,000 | 28,700,000 | -48,000 | 6,833,000 | 4,881,000 | 834,000 | 194,000 | 5,394,000 | 1,933,000 | 7,605,000 | 4,954,000 | 6,170,000 | 2,289,000 | 3,811,000 | 2,749,000 | 1,258,000 | 511,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on assets and liabilities held for sale | -2,300,000 | 115,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on fair value remeasurement of contingent consideration | 11,500,000 | 1,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales, excluding amortization of acquired intangible assets | 331,950,000 | 460,800,000 | 421,000,000 | 446,000,000 | 509,200,000 | 370,000,000 | 366,200,000 | 384,600,000 | 378,500,000 | 416,900,000 | 370,300,000 | 313,000,000 | 331,821,000 | 310,028,000 | 286,120,000 | 312,431,000 | 297,265,000 | 302,639,000 | 291,887,000 | 279,245,000 | 258,553,000 | 234,696,000 | 230,728,000 | 133,749,000 | 133,828,000 | 139,358,000 | 139,112,000 | 133,197,000 | 343,253,000 | 123,527,000 | 100,503,000 | 103,113,000 | 106,985,000 | 97,055,000 | 288,618,000 | 93,486,000 | 90,721,000 | 98,197,000 | 101,161,000 | 107,493,000 | 92,401,000 | 100,934,000 | 87,566,000 | 81,613,000 | 84,063,000 | 81,950,000 | |||||||||||||||||||||||||||||||||||||
| amortization of acquired intangible assets | 123,300,000 | 281,900,000 | 107,400,000 | 103,900,000 | 139,800,000 | 108,900,000 | 117,500,000 | 448,500,000 | 104,200,000 | 99,700,000 | 92,900,000 | 88,800,000 | 96,628,000 | 98,065,000 | 92,004,000 | 95,903,000 | 107,246,000 | 122,431,000 | 116,826,000 | 143,258,000 | 109,424,000 | 99,998,000 | 82,225,000 | 51,301,000 | 50,948,000 | 53,013,000 | 52,282,000 | 45,961,000 | 159,219,000 | 49,347,000 | 55,136,000 | 53,216,000 | 53,148,000 | 48,889,000 | 238,464,000 | 51,347,000 | 93,234,000 | 89,248,000 | 90,631,000 | 94,464,000 | 72,869,000 | 74,781,000 | 70,925,000 | 65,689,000 | 60,961,000 | 59,920,000 | 60,020,000 | 60,011,000 | 76,260,000 | 70,707,000 | 73,559,000 | 75,990,000 | 77,078,000 | 75,677,000 | |||||||||||||||||||||||||||||
| unconsolidated joint business | 333,898,000 | 337,181,000 | 337,510,000 | 330,611,000 | 304,530,000 | 290,678,000 | 303,296,000 | 296,885,000 | 269,416,000 | 303,210,000 | 288,785,000 | 264,606,000 | 280,948,000 | 287,792,000 | 284,630,000 | 284,552,000 | 730,126,000 | 266,471,000 | 216,458,000 | 256,124,000 | 306,371,000 | 254,928,000 | 810,944,000 | 283,919,000 | 275,570,000 | 278,818,000 | 303,214,000 | 298,979,000 | 278,822,000 | 247,223,000 | 253,707,000 | 234,637,000 | 230,590,000 | 207,164,000 | 217,568,000 | 203,820,000 | 206,095,000 | 183,380,000 | 131,746,000 | 181,597,000 | 184,934,000 | 160,453,000 | |||||||||||||||||||||||||||||||||||||||||
| gain on sale of rights | 4,620,000 | 4,379,000 | 3,900,000 | 3,859,000 | 7,579,000 | 6,949,000 | 5,319,000 | 5,051,000 | 15,073,000 | 31,719,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to biogen idec inc. | 883,464,000 | 856,858,000 | 714,506,000 | 479,956,000 | 457,306,000 | 487,616,000 | 490,670,000 | 426,749,000 | 292,127,000 | 398,400,000 | 386,846,000 | 302,661,000 | 882,602,000 | 351,826,000 | 288,034,000 | 294,331,000 | 293,438,000 | 217,442,000 | 692,469,000 | 277,663,000 | 142,845,000 | 243,987,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic earnings per share attributable to biogen idec inc. | 3.75 | 3.63 | 3.02 | 2.03 | 1.93 | 2.06 | 2.07 | 1.8 | 1.24 | 1.68 | 1.62 | 1.26 | 3.64 | 1.45 | 1.19 | 1.22 | 1.13 | 0.8 | 2.41 | 0.96 | 0.49 | 0.85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share attributable to biogen idec inc. | 3.73 | 3.62 | 3.01 | 2.02 | 1.92 | 2.05 | 2.06 | 1.79 | 1.23 | 1.67 | 1.61 | 1.25 | 3.61 | 1.43 | 1.18 | 1.2 | 1.12 | 0.8 | 2.4 | 0.95 | 0.49 | 0.84 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restructuring charge | 803,000 | 1,139,000 | 283,000 | 17,223,000 | 1,803,000 | 16,587,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| fair value adjustment of contingent consideration | 2,277,000 | 3,629,000 | 9,456,000 | 12,858,000 | 1,258,000 | 33,565,000 | 2,500,000 | 2,200,000 | 1,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax expense | 384,514,000 | 1,230,448,000 | 480,766,000 | 399,085,000 | 426,234,000 | 396,892,000 | 295,303,000 | 939,141,000 | 393,538,000 | 237,594,000 | 311,804,000 | 214,708,250 | 321,125,000 | 291,334,000 | 246,374,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to biogen idec | 254,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share attributable to biogen idec | 1.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| costs and expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total costs and expenses | 816,822,000 | 805,171,000 | 2,345,581,000 | 736,340,000 | 870,375,000 | 731,526,000 | 743,953,000 | 747,114,000 | 696,647,000 | 696,182,000 | 630,870,000 | 660,021,000 | 566,736,000 | 534,218,000 | 516,623,000 | 506,164,000 | 782,056,000 | 438,186,000 | 539,554,000 | 575,046,000 | 559,333,000 | 512,528,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to noncontrolling interest, net of tax | 1,211,000 | 2,551,000 | 4,991,000 | 1,939,000 | 2,040,000 | 2,592,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other revenues | 8,727,500 | 34,910,000 | 26,749,000 | 24,257,000 | 33,864,000 | 35,725,000 | 30,136,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| in-process research and development | 6,250,000 | 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic earnings per share | 0.7 | 0.71 | 0.71 | 0.55 | 0.67 | 0.41 | 0.55 | 0.39 | 0.32 | 0.46 | -0.5 | 0.36 | 0.17 | 0.08 | 0.1 | 0.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share | 0.7 | 0.7 | 0.7 | 0.54 | 0.65 | 0.41 | 0.54 | 0.38 | 0.32 | 0.45 | -0.5 | 0.36 | 0.16 | 0.08 | 0.1 | 0.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| facility impairments and gain on sale | -230,750 | 175,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on settlement of license agreement | -8,548,000 | -34,192,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision and cumulative effect of accounting change | 295,061,000 | 174,114,000 | 238,026,000 | -100,209,000 | 191,654,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before cumulative effect of accounting change | 201,150,000 | 119,381,000 | 186,140,000 | 131,501,000 | 108,556,000 | 156,599,000 | -170,613,000 | 119,190,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cumulative effect of accounting change, net of income tax | -3,778,999.99 | 3,779,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of long lived assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| shares used in calculating: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of long-lived assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax expense and cumulative effect of accounting change | 203,394,000 | 181,071,000 | 219,647,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| royalty | 15,178,500 | 21,867,000 | 18,286,000 | 20,561,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| corporate partner | 750,500 | 2,709,000 | -421,000 | 715,000 | 132,000 | 131,000 | 144,000 | 3,016,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of product revenues, excluding amortization of acquired intangible assets | 52,298,750 | 65,742,000 | 77,060,000 | 66,391,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of royalty revenues | 771,250 | 1,050,000 | 933,000 | 1,103,000 | 1,237,000 | 1,203,000 | 849,000 | 1,128,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| facility impairments and loss on sale | -799,000 | -298,000 | 15,208,000 | 21,046,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax provision | 72,464,000 | 11,477,500 | 5,172,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| royalties | 21,593,000 | 23,117,000 | 21,734,000 | 26,749,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of product revenues | 64,270,750 | 88,358,000 | 70,244,000 | 98,481,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision | 37,764,750 | 32,357,000 | 52,352,000 | 66,348,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on sale of manufacturing facility | 75,565,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | 17,848,000 | 22,890,000 |
We provide you with 20 years income statements for Biogen stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Biogen stock. Explore the full financial landscape of Biogen stock with our expertly curated income statements.
The information provided in this report about Biogen stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.